Dr. J. William Lindsey, Director of Multiple Sclerosis and Neuroimmunology at McGovern Medical School, UTHealth Houston, discusses how these social determinants of health impact the disease. (2:35) Is ...
Phase 3 trial results for rolapitant, a novel NK-1 receptor antagonist, in the prevention of chemotherapy-induced nausea and vomiting (CINV) in subjects receiving highly emetogenic chemotherapy (HEC).
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, will present new findings at the American College of Gastroenterology (ACG) 2024 Annual ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results